Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Revenue (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Revenue for 6 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 286.02% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.3 million, a 266.65% increase, with the full-year FY2025 number at $10.3 million, up 266.65% from a year prior.
  • Revenue was $2.6 million for Q4 2025 at TScan Therapeutics, up from $2.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $7.2 million in Q4 2023 to a low of $536000.0 in Q2 2024.
  • A 5-year average of $2.8 million and a median of $2.9 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 731.72% in 2021, then tumbled 90.78% in 2024.
  • TScan Therapeutics' Revenue stood at $2.9 million in 2021, then rose by 8.44% to $3.1 million in 2022, then soared by 132.99% to $7.2 million in 2023, then crashed by 90.78% to $665000.0 in 2024, then surged by 286.02% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Revenue are $2.6 million (Q4 2025), $2.5 million (Q3 2025), and $3.1 million (Q2 2025).